SCHEMBL1067374

SCHEMBL1067374

CCOC(=O)/C=C(\CBr)Oc1cccc(OCC)c1F

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
CYP2A6 P11509 1/20 0.35
RAB9A P51151 2/20 0.34
CYP1A2 P05177 2/20 0.33
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
KDM4E B2RXH2 2/20 0.33
HSD17B10 Q99714 2/20 0.33
GRM5 P41594 1/20 0.33
FGFR1 P11362 1/20 0.33
FGFR2 P21802 1/20 0.33
NPC1 O15118 1/20 0.33
GAA P10253 3/20 0.33
NPSR1 Q6W5P4 2/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP2C9 P11712 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067378 1.00 GLA (0.35) GLAL3MBTL1CYP2A6RAB9ACYP1A2
SCHEMBL1067380 1.00 GLA (0.35) GLAL3MBTL1CYP2A6RAB9ACYP1A2
SCHEMBL1068773 0.89 SMN1; SMN2 (0.38) GLAL3MBTL1RAB9ACYP1A2KDM4E
SCHEMBL1069036 0.89 CYP1A2 (0.34) L3MBTL1RAB9ACYP1A2KDM4EHSD17B10
SCHEMBL1068771 0.89 SMN1; SMN2 (0.38) GLAL3MBTL1RAB9ACYP1A2KDM4E
SCHEMBL1068160 0.89 CYP1A2 (0.34) L3MBTL1RAB9ACYP1A2KDM4EHSD17B10
SCHEMBL1068772 0.89 SMN1; SMN2 (0.38) GLAL3MBTL1RAB9ACYP1A2KDM4E
SCHEMBL1069040 0.89 CYP1A2 (0.34) L3MBTL1RAB9ACYP1A2KDM4EHSD17B10
SCHEMBL1069323 0.88 MAPT (0.34) L3MBTL1RAB9ACYP1A2KDM4EHSD17B10
SCHEMBL1069322 0.88 MAPT (0.34) L3MBTL1RAB9ACYP1A2KDM4EHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 GLA 186/4885L3MBTL1 4431/4885CYP2A6 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.